Understanding Zepbound and Mounjaro Targeting long-term weight management and diabetes control, both Zepbound and Mounjaro stand at the forefront of GLP-1-based treatments
Their fat-burning effects can also be targeted to specific parts of the body, such as around the belly
We are entering an era where treatments are not only managing conditions but actively improving overall metabolic health and long-term outcomes
Stopping peptide therapy generally does not blunt the bodys baseline growth hormone production, but these medications can still carry risks
The Monitoring Program includes substances which are not on the Prohibited List, but that WADA wishes to monitor in order to detect potential patterns of misuse in sport. A spokesperson for Novo Nordisk said in a statement that the pharmaceutical company, which produces and distributes GLP-1s, agreed with WADAs decision to monitor GLP-1 usage: We are supportive of the WADA recommendation, and we strongly discourage use/promotion outside the indicated population and approved label. Advertisement A spokesperson for Eli Lilly, another company that manufactures and distributes GLP-1s, said: Zepbound (tirzepatide) and Foundayo (orforglipron) are indicated for use, along with diet and exercise, for adults with obesity or overweight and a weight-related comorbidity
I see it appear suddenly and unpredictably in both new starters and long-term users, suggesting multiple overlapping mechanisms are usually at play rather than a single isolated cause